Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248612 · ClinicalTrials.gov registry record · Phase 2
Psychosocial and Medication Treatment for Anxiety in Alcoholism
A Phase 2 study, sponsored by Boston Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT00248612 is a Phase 2 study that has completed, run by Boston Medical Center. The registered enrollment target is 162 participants.
The verdict
NCT00248612, a Phase 2 study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The proposed project is written as a "typical clinical practice" test and is a fully-controlled trial of a combined anxiety-focused CBT and pharmacotherapy (venlafaxine; CBT-VEN) delivered for patients with comorbid alcohol-use and anxiety disorders. The CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication. One hundred and eighty participants will be recruited and, subsequent to a platform of outpatient treatment for alcoholism, will be randomly assigned to a 12-week treatment condition. All treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo. The treatments will conclude with a 2-week medication/placebo taper. Follow-up assessments will be conducted at post-treatment and at 3, 6, 9, and 12-months. The long-term objectives of this research are to develop a real-world combination of psychosocial and pharmacological treatments for patients with comorbid alcohol-use and anxiety disorders that compromise prognosis, and to evaluate the effectiveness of combined psychosocial and pharmacological treatments that target anxiety among patients with this comorbidity.
Interventions
- BEHAVIORAL CBT
- DRUG Venlafaxine
- OTHER Progressive muscle relaxation therapy (PMR)
- OTHER Placebo medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2003-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00248612
The ClinicalTrials.gov registry entry for NCT00248612 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CBT is the first listed.
NCT00248612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00248612 about?
NCT00248612 is a clinical study titled "Psychosocial and Medication Treatment for Anxiety in Alcoholism". The proposed project is written as a "typical clinical practice" test and is a fully-controlled trial of a combined anxiety-focused CBT and pharmacotherapy (venlafaxine; CBT-VEN) delivered for patients with comorbid alcohol-use and anxiety disorders. The CBT and pharmacotherapy will be contrasted wi...
What is the current status of trial NCT00248612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2003-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00248612?
The interventions under investigation include: CBT (BEHAVIORAL), Venlafaxine (DRUG), Progressive muscle relaxation therapy (PMR) (OTHER), Placebo medication (OTHER).
Who is sponsoring clinical trial NCT00248612?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.